The Stratified Medicine Group focuses on the following areas:

  • Characterisation of a molecular group in solid cancers that represents an innate immune response to DNA damage through the STING pathway.
  • Development of a biomarker for anti-angiogenic agents
  • Development of a biomarker for MEKK pathway activation
  • Identification of a prognostic biomarker for early prostate cancer
  • Development of new cell lines for pre-clinical modelling of ovarian and prostate cancer